As cannabis finds its place back into modern human culture quickly, there is much still to be learned. As the science grows and adapts to modern need and expectations, the “can we” may be out-pacing the “should we.” On the other hand, there are circumstances where modern culture really “should be” and is handicapped by years of misinformed stigma.
Here, a few controversial questions about cannabis:
Should teachers be allowed to use cannabis around children?
Should spiritual leaders be allowed to use cannabis, as they have for millennia?
Should taxi drivers be allowed to use cannabis on the job?
Should pilots be allowed to use cannabis?
To explore related information, click the keywords below:
Benjamin Caplan, MDVideo: Controversial Questions in Cannabis Today
Title: Novel approaches in clinical development of cannabinoid drugs
A pamphlet has recently been published that highlights new approaches in the clinical development of cannabinoid-based therapies. The pamphlet begins with a look into how current cannabinoids affect patients based on gender, stress, physiological variations, and also delves into how cannabis works on the body in general.
A novel therapy that features an oral version of tetrahydrocannabinol (THC) and a synthetic activator of cannabinoid-receptor-1 (CB1) is explored in this piece and frames it to be a promising future therapy. The pharmacological properties of these two novel therapies were optimized during development after various analysis techniques, forming medications that the authors hope to see in future clinical trials.
Although the authors remain hopeful that their cannabis-based therapies will reach clinical trials soon, trials featuring cannabinoids are difficult to test in a formal setting because of a dire lack of funding. The federal government still lists cannabis as a Schedule I substance, under the Controlled Substances Act, meaning that the federal government does not support the idea that cannabis has any medical use. Considering the legal status of cannabis, only privately-funded studies are able to take place, and unfortunately, that leaves cannabis research in an area of complete bias and prohibitively underfunded. Considering the massive literature supporting a myriad of novel therapeutic benefits, this is a costly reality to the health and well-being of millions.
A recent letter to the editor exposes the large discrepancy between the number of registered medical marijuana patients and those who self-reported medical cannabis use. Estimates given by the National Survey on Drug Use and Health (NSDUH) suggest that 2.5% of Americans over the age of 12 used medical cannabis in 2013-2015 but a study from 2016 found that only 641,176 people were licensed to receive medical cannabis, a prevalence of 0.4%. If the numbers published by the NSDUH are accurate then states may need to delve into how so many people are accessing medical cannabis without proper licensing in order to better regulate the supply. If the numbers are extrapolated to 2019 and include all states where medical cannabis use in legal then more than 6.2 million people should be licensed but may not be.
Medical cannabis can be difficult to acquire due to its cost, post-legalization. Although medical cannabis in Massachusetts is readily available with a large number of dispensaries across the state, the cost of obtaining a doctor’s recommendation, complying with state fees, and then paying for the cannabis at a dispensary can be too much for some patients. Although MA will soon be waving the state fee, to obtaining a license, clinicians are still expensive and without the support of the federal government allowing national insurance companies to cover medical cannabis the costs still add up quickly. Fortunately, some dispensaries are designed to cater to those who need financial support.
Medical marijuana is legal in 33 states, and recreational marijuana is legal in 11. But on a federal level, the use and possession of marijuana is illegal for any purpose. The illegal status of cannabis prohibits research opportunities and hinders the safety of cannabis sales.
Watch this video for 4 reasons to legalize marijuana on a federal level
Benjamin Caplan, MDVideo: Legalization of Cannabis?
A sneak peek at the latest news coming about solo sciences, inc!
Imagine a future of cannabis, where consumers have the control of purchase decisions, based on accurate information about the brand and products they may want, and tamper-proof, third-party verification that what we are buying is actually what the package says it is? (and then… consider that this concept applies to products beyond cannabis, from food to beauty products, toys, entertainment…)
“The world of cannabis is murky, unpredictable, and often not safe,” said Ashesh Shah, CEO and founder of solo sciences and a former CIA profiler. “As brands and governments are struggling to fight the illicit market, we created solo* to solve that problem by creating transparency into what cannabis providers are actually selling to consumers. solo* is designed to keep people out of the dark when it comes to what they’re consuming and putting into their bodies, so they feel secure and knowledgeable about the products they’re purchasing.”
Though UK doctors have been able to prescribe cannabis since November 2018, very few prescriptions have been issued, because most forms of medical cannabis have not been approved by the government.
In response to thousands of disappointed patients, the House of Commons Health and Social Care Committee called for immediate clinical trials focusing on the treatment of intractable childhood epilepsy.
Kudos to the Massachusetts Cannabis Control Commission for implementing a regulatory standard to ensure a sustained opportunity for education and knowledge improvement into the state’s cannabis industry and community.
Massachusetts has consistently shown outstanding leadership in the healthcare arena, and it’s thrilling to see that cannabis is treated no differently.
Already leading the cutting edge of research, education, and cannabis formulation development, CED Foundation is ready & eager to support our industry colleagues with education and guidance, here in MA, and worldwide.
Benjamin Caplan, MDMassachusetts enshrines education requirements into the cannabis standard of care
Title: Impact of N, P, K and humic acids supplementation on the chemical profile of medical cannabis (Cannabis sativa L)
A recent study has come out revealing the effects of nutritional supplements (plant food) on cannabinoid content during the growth of the cannabis plant.
Researchers enhanced nutritional supplements such as humic acids and inorganic nitrogen and potassium and determined that the changes in supplement levels caused variations in the cannabinoid content of the plant organs. This research has demonstrated that maintaining specific nutritional supplements effects the chemical properties of cannabis plants and may play a role in standardizing the cannabinoid content in plants, no matter the region of growth. This knowledge may one day help cultivators with the process of standardizing cultivars, and perhaps help organize strain names and content across state lines.
This work spotlights the inconsistency between cannabis plants, even if they share the same name. The nutrients cannabis plants grow in have been proven to alter the cannabinoid content which changes (sometimes drastically) the effects felt by patients who consume that plant. Growers or enthusiasts who grow cannabis at home may be buying seeds from a known strain, but the same seeds produce a completely different strain, depending on the growing conditions. Standardizing growth conditions will hopefully help cultivators produce strains of the same name with consistent cannabinoid content, making buying safer and somewhat more uniformly regulatable.
Tweet: A recent study has come out revealing the effects of #nutritional supplements on #cannabinoid content during #cannabis plant growth. Read this and other linked studies: